Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Up 58.7% in May

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 4,598 shares, an increase of 58.7% from the May 14th total of 2,897 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 21,087 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bone Biologics presently has an average rating of “Sell”.

Bone Biologics Price Performance

Shares of NASDAQ:BBLG traded down $0.06 during midday trading on Tuesday, reaching $1.38. 33,792 shares of the company’s stock were exchanged, compared to its average volume of 21,108. The stock has a market cap of $2.48 million, a price-to-earnings ratio of -0.62 and a beta of 0.93. Bone Biologics has a fifty-two week low of $1.05 and a fifty-two week high of $6.75. The firm’s 50 day simple moving average is $1.29 and its two-hundred day simple moving average is $1.42.

Bone Biologics (NASDAQ:BBLG) last posted its earnings results on Thursday, May 14th. The company reported ($0.43) EPS for the quarter, meeting analysts’ consensus estimates of ($0.43). Equities research analysts predict that Bone Biologics will post -1.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bone Biologics

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC increased its stake in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the period. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 34.30% of the company’s stock.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.